Main Article Content

E Ferreira
M Gillet
J Lelièvre
J-F Bussières


Ondansetron, pregnancy, hyperemesis gravidarum, case series, birth defects


This is a descriptive retrospective case series of 14 pregnant women treated with ondansetron for hyperemesis gravidarum (HG) at CHU Sainte-Justine, from January 2002 to October 2011. Two of the patients received ondansetron during two separate pregnancies. Both pregnancies were analyzed separately for the purposes of this study. Another woman had twins who were included in the analysis. Therefore, the outcomes of 16 pregnancies and 17 newborns are presented. The patients were on average 28.1 ± 4.6 years old and were admitted to the hospital 5.0 ± 4.0 times. All patients who received ondansetron had previously been treated using the standard HG protocol to which they had not optimally responded. Ondansetron was initiated on average at 11.8 ± 4.8 weeks’ gestation. In seven cases, administration was carried out during organogenesis. We observed 16 live births, including a set of twins, and one minor birth defect (isolated atrial and ventricular septal defects) reported after a second trimester exposure. Mean gestational age at birth was 36.9 ± 3.4 weeks and mean birth weight was 2.85±0.86 kg. We also noted six other pregnancy or neonatal outcomes (intrauterine growth retardation [IUGR] for each twin and a in a single pregnancy, a transient tachypnea, a mild hydrocele, and an extrarenal pelvis). Furthermore, we noted two premature births, one at 24 weeks of gestation and her infant died in the first weeks of life due to complications of prematurity and a second birth at 36 2/7 weeks of gestation. Teratogenicity associated with the use of ondansetron has so far not been shown in humans. This case series adds information on ondansetron use during pregnancy. However, until we have more published data, ondansetron should be used as a second-line agent for the management of HG.

Abstract 500 | PDF Downloads 174


1. Miller F. Nausea and vomiting in pregnancy: the problem of perception--is it really a disease? Am J Obstet Gynecol 2002;186 (5 Suppl Understanding):S182-3.
2. Goodwin TM. Hyperemesis gravidarum. Clin Obstet Gynecol 1998;4:597-605.
3. Poursharif B, Korst LM, Macgibbon KW, Fejzo MS, Romero R, Goodwin TM. Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. Contraception 2007;76(6):451-5.
4. Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am 2008;35(3):401-17.
5. Bailit JL. Hyperemesis gravidarium: Epidemiologic findings from a large cohort. Am J Obstet Gynecol 2005;193(3 Pt 1):811-4.
6. Dodds L, Fell DB, Joseph KS, Allen VM, Butler B. Outcomes of pregnancies complicated by hyperemesis gravidarum. Obstet Gynecol 2006;107(2 Pt 1):285-92.
7. Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007;110(3):695-703.
8. Ismail SK, Kenny L. Review on hyperemesis gravidarum. Best Pract Res Clin Gastroenterol 2007;21(5):755-69.
9. Festin M. Nausea and vomiting in early pregnancy. Clin Evid 2009;6:1405-25.
10. Lacasse A, Lagoutte A, Ferreira E, Berard A. Metoclopramide and diphenhydramine in the treatment of hyperemesis gravidarum: Effectiveness and predictors of rehospitalisation. Eur J Obstet Gynecol Reprod Biol 2009;143(1):43-9.
11. Tan PC, Omar SZ. Contemporary approaches to hyperemesis during pregnancy. Curr Opin Obstet Gynecol 2011;23(2):87-93.
12. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62(6):385-92.
13. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317(7162):839-43.
14. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A pathophysiologic approach. 3rd edition. Stamford: Appleton and Lange, 1997. 751-65.
15. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111 Suppl 8A:106S-112S.
16. Moore KL, Persaud TVN. Before we are born: Essentials of embryology and birth defects. 6th edition. Philadelphia: Saunders, Elsevier Science, 2003. 62-75.
17. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;50(4): 781– 800.
18. Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996;174(5):1565-8.
19. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111(9):940-3.
20. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 8th edition Philadelphia: Lippincott Williams and Wilkins, 2008. 1368.
21. Asker C, Norstedt Wikner B, Kallen B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61(12):899-906.
22. Siu SS, Yip SK, Cheung CW, Lau TK. Treatment of intractable hyperemesis gravidarum by ondansetron. Eur J Obstet Gynecol Reprod Biol 2002;105(1):73-4.
23. Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 1996;72(853):688-9.
24. Guikontes E, Spantideas A, Diakakis J. Ondansetron and hyperemesis gravidarum. Lancet 1992;340(8829):1223.
25. Siu SS, Chant MT, Lau TK. Placental transfer of ondansetron during early human pregnancy. Clin Pharmacokinet 2006;45(4):419-23.